专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011041395A2 SILK NANOSPHERES AND MICROSPHERES AND METHODS OF MAKING SAME 审中-公开
标题翻译：丝素纳米微粒和微球及其制备方法
公开(公告)号：WO2011041395A2
公开(公告)日：2011-04-07
申请号：PCT/US2010/050698
申请日：2010-09-29
申请人： TRUSTEES OF TUFTS COLLEGE , WANG, Xiaoqin , KAPLAN, David L
发明人： WANG, Xiaoqin , KAPLAN, David L
IPC分类号： B82B3/00 , B82B1/00
CPC分类号： A61K9/5169 , A61K9/14 , A61K9/1605 , A61K9/1647 , A61K9/5052 , A61K9/5089 , A61K9/5192 , A61K31/352 , Y10T428/2982
摘要： The present invention provides for methods of preparing silk nanoparticles and microparticles, methods of encapsulating an active agent into the silk nano- and microparticles and compositions comprising these silk particles. In particular, the silk spheres are prepared from phase separation of silk and polyvinyl alcohol (PVA), without exposure to an organic solvent. The method employs a chemical, PVA, which is an FDA-approved ingredient in drug formulations. Different parameters can be adjusted to control the size and shape of the silk spheres during the fabrication process. The silk particle compositions of the present invention may also encapsulate active agents or chemicals. Such compositions allow the active agents to be controllably and sustainably released to the target organs or tissues. The silk composition entrapping active agents also provides for a long-term storage medium for the active agents so entrapped. The silk nano- and microparticles of the present invention are thus suitable for a variety of biomedical and pharmaceutical applications, such as drug delivery or tissue engineering.
摘要翻译：本发明提供了制备丝纳米颗粒和微粒的方法，将活性剂包封在丝纳米和微粒中的方法和包含这些丝颗粒的组合物。特别地，丝球是通过丝和聚乙烯醇（PVA）的相分离制备的，而不暴露于有机溶剂。该方法采用化学品PVA，它是FDA批准的药物制剂成分。可以调整不同的参数，以在制造过程中控制丝球的尺寸和形状。本发明的丝粒组合物也可以包封活性剂或化学物质。这样的组合物允许活性剂可控地和可持续地释放到靶器官或组织。包埋活性剂的丝状组合物还为被捕获的活性剂提供长期储存介质。因此，本发明的丝素纳米颗粒和微粒子适用于各种生物医学和药物应用，例如药物递送或组织工程。

2. 发明申请

WO2009126346A3 METHODS FOR PREVENTION AND TREATMENT OF INFECTIONS WITH SUPRAPHYSIOLOGICAL DOSES OF MANNAN-BINDING LECTIN (MBL) AND FICOLIN-MBL FUSION PROTEINS 审中-公开
公开(公告)号：WO2009126346A3
公开(公告)日：2009-10-15
申请号：PCT/US2009/031189
申请日：2009-01-16
申请人： THE GENERAL HOSPITAL CORPORATION , MICHELOW, Ian, C. , SCHMIDT, Emmett, V. , TAKAHASHI, Kazue
发明人： MICHELOW, Ian, C. , SCHMIDT, Emmett, V. , TAKAHASHI, Kazue
IPC分类号： A61K38/08 , A61P31/04 , A61P31/12 , A61K38/17
摘要： The present invention provides methods of treatment and/or prevention of infections, for example, viral and bacterial infections, in individuals, wherein the method comprises administering a supraphysiological amount of mannose-binding lectin (MLB) and/or ficolin-MBL fusion protein to an individual afflicted with an infection or at risk of an infection, such as a bacterial or a viral infection. For example, methods for treatment and/or prevention of Ebola virus infection are provided.

3. 发明申请

WO2009048932A2 METHODS TO REGULATE MIRNA PROCESSING BY TARGETING LIN-28 审中-公开
标题翻译：通过瞄准LIN-28来调节米拉加工的方法
公开(公告)号：WO2009048932A2
公开(公告)日：2009-04-16
申请号：PCT/US2008/079175
申请日：2008-10-08
申请人： CHILDREN'S MEDICAL CENTER CORPORATION , GREGORY, Richard I , DALEY, George Q , VISWANATHAN, Srinivas R
发明人： GREGORY, Richard I , DALEY, George Q , VISWANATHAN, Srinivas R
IPC分类号： C12N15/11 , A61K31/7088 , A61K39/395
CPC分类号： C12N15/111 , C12N15/113 , C12N2310/111 , C12N2310/14 , C12N2320/50 , C12Q1/6886 , C12Q2600/106 , C12Q2600/158 , C12Q2600/178
摘要： The present invention relates generally to methods to regulate microRNA (miRNA) biogenesis, in particular the regulation of the processing of pri-miRNA to mature miRNA by Lin-28 and/or variants such as Lin28B. In particular, the present invention relates to methods and compositions comprising at least one agent which inhibits Lin-28 function or activity and/or expression to increase the processing of pri-mRNA to mature miRNA. More specifically, one aspect of the invention is directed to treating and/or preventing cancer in a subject by administering an agent that inhibits Lin-28 activity or expression to a subject, preferably a human subject.
摘要翻译：本发明一般涉及调节微小RNA（miRNA）生物发生的方法，特别是通过Lin-28和/或变体如Lin28B调节pri-miRNA对成熟miRNA的加工。特别地，本发明涉及包含至少一种抑制Lin-28功能或活性和/或表达以增加pri-mRNA对成熟miRNA的加工的试剂的方法和组合物。更具体地，本发明的一个方面涉及通过给受试者，优选人受试者施用抑制Lin-28活性或表达的试剂来治疗和/或预防受试者的癌症。

4. 发明申请

WO2008147958A1 METHOD OF TREATMENT TO IMPROVE CONCENTRATION AND/OR MEMORY IN A SUBJECT IN NEED THEREOF 审中-公开
标题翻译：治疗方法以改善需要的受试者的浓度和/或记忆
公开(公告)号：WO2008147958A1
公开(公告)日：2008-12-04
申请号：PCT/US2008/064658
申请日：2008-05-23
申请人： THOMAS JEFFERSON UNIVERSITY , SPERLING, Michael R , TRACY, Joseph I , LIM, Young Hyun
发明人： SPERLING, Michael R , TRACY, Joseph I , LIM, Young Hyun
IPC分类号： A61N5/06 , A61M21/00
CPC分类号： A61N5/0618 , A61M21/00 , A61M2021/0033 , A61M2021/0044 , A61N2005/0662
摘要： The present invention is directed to a method of treatment to improve at least one of concentration, memory, cognitive performance, and stress-relief in a subject in need thereof by controlled administration of synchronized flashes of light and pulsed tones.
摘要翻译：本发明涉及一种治疗方法，其通过控制施用同步闪光的光和脉冲色调来改善有需要的受试者中的浓度，记忆，认知表现和应激消除中的至少一种。

5. 发明申请

WO2010144678A2 GENERATION OF VASCULARIZED HUMAN HEART TISSUE AND USES THEREOF 审中-公开
标题翻译：血管化人心脏组织的产生及其用途
公开(公告)号：WO2010144678A2
公开(公告)日：2010-12-16
申请号：PCT/US2010/038134
申请日：2010-06-10
申请人： THE GENERAL HOSPITAL CORPORATION , CHIEN, Kenneth R , BU, Lei , JIANG, Xin , LUI, Kathy Oi Lan
发明人： CHIEN, Kenneth R , BU, Lei , JIANG, Xin , LUI, Kathy Oi Lan
IPC分类号： C12N5/071 , C12N5/02 , C07K14/475 , A61P9/00
CPC分类号： C12N5/0662 , A61K35/12 , C12N5/0657 , C12N2501/15 , C12N2501/165 , C12N2501/415 , C12N2506/02
摘要： The present invention relates to the generation of vascularized human heart tissue from human primordial Islet1-positive (ISL1+) progenitors, and more particularly the generation of vascularized human heart tissue from human primordial Islet1+ cardiovascular stem cells which are positive for markers ISL1+/NKX2.5-/KDR-. One aspect of the invention relates to isolation of human ISL1+ primordial cells from human pluripotent cells, such as human ES cells or other human pluripotent stem cell sources, wherein the human ISL1+ primordial cells can differentiate into three different lineages; cardiomyocyte lineages, endothelial lineages and smooth muscle lineages. Another aspect relates to use and implantation of the human primordial ISL1+ progenitors into an animal model to generate human vascularized heart tissue, and more particularly, the production of an in vivo humanized model of vascular disease. One embodiment relates to the use of an in vivo humanized model of vascular disease as an assay, for example to assess drug toxicity and/or identify agents which increase and decrease coronary blood flow to the human vascularized heart tissue. Another embodiment relates to the therapeutic use of human primordial ISL1+ progenitors, for example, in one embodiment the invention provides methods for the treatment cardiovascular disorders and/or congenital heart disease in a subject comprising transplanting into subjects vascularized human heart tissue generated from human ISL1+ progenitors.
摘要翻译：本发明涉及从人原始Islet1阳性（ISL1 +）祖细胞产生血管化人心脏组织，更具体地说，从人原代ISL1 + / NKX2.5阳性的人原始Islet1 +心血管干细胞产生血管化人心脏组织 - / KDR-。本发明的一个方面涉及从人多能细胞例如人ES细胞或其他人多能干细胞来源分离人ISL1 +原始细胞，其中人ISL1 +原始细胞可分化成三种不同谱系; 心肌细胞谱系，内皮谱系和平滑肌谱系。另一方面涉及将人原始ISL1 +祖细胞用于和植入动物模型中以产生人血管化的心脏组织，更具体地，涉及血管疾病的体内人源化模型的产生。一个实施方案涉及血管疾病的体内人源化模型的用途作为测定，例如用于评估药物毒性和/或鉴定增加和减少冠心病血液流向人血管化心脏组织的药剂。另一个实施方案涉及人原始ISL1 +祖细胞的治疗用途，例如，在一个实施方案中，本发明提供了治疗受试者心血管疾病和/或先天性心脏病的方法，所述方法包括移植入受试者从人ISL1 +祖细胞产生的血管化人心脏组织。

6. 发明申请

WO2010081131A1 COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TYPE 2 DIABETES 审中-公开
标题翻译：用于诊断和治疗2型糖尿病的组合物和方法
公开(公告)号：WO2010081131A1
公开(公告)日：2010-07-15
申请号：PCT/US2010/020725
申请日：2010-01-12
申请人： AMERICAN TYPE CULTURE COLLECTION , GELBER, Cohava , LIU, Liping , XIE, Zhidong , IKONOMI, Pranvera , SIMMS, John R , AUGE, Catherine R
发明人： GELBER, Cohava , LIU, Liping , XIE, Zhidong , IKONOMI, Pranvera , SIMMS, John R , AUGE, Catherine R
IPC分类号： A61K38/00
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/158
摘要： The present invention relates generally to the identification of biological markers associated with an increased risk of developing Diabetes, as well as methods of using such biological markers in diagnosis and prognosis of Diabetes. The biological markers of the invention may indicate new targets for therapy or constitute new therapeutics for the treatment or prevention of Diabetes.
摘要翻译：本发明一般涉及与发展中的糖尿病风险增加相关的生物标志物的鉴定，以及在糖尿病诊断和预后中使用这些生物标志物的方法。本发明的生物标志物可以指示治疗的新靶标或构成用于治疗或预防糖尿病的新治疗剂。

7. 发明申请

WO2010042856A2 TISSUE ENGINEERED MYOCARDIUM AND METHODS OF PRODUCTION AND USES THEREOF 审中-公开
标题翻译：组织工程心肌梗塞及其生产方法及其用途
公开(公告)号：WO2010042856A2
公开(公告)日：2010-04-15
申请号：PCT/US2009/060224
申请日：2009-10-09
申请人： THE GENERAL HOSPITAL CORPORATION , PRESIDENT AND FELLOWS OF HARVARD COLLEGE , CHIEN, Kenneth R , DOMIAN, Ibrahim J , CHIRAVURI, Murali , VAN DER MEER, Peter , PARKER, Kevin Kit , FEINBERG, Adam W
发明人： CHIEN, Kenneth R , DOMIAN, Ibrahim J , CHIRAVURI, Murali , VAN DER MEER, Peter , PARKER, Kevin Kit , FEINBERG, Adam W
IPC分类号： A61L27/38 , A61L27/54 , A61L27/24 , A61L27/14 , A61F2/08
CPC分类号： A61L27/3804 , A61L27/507 , A61L27/54 , A61L2300/252 , A61L2300/258 , A61L2300/414 , A61L2300/426 , A61L2300/43 , A61L2300/432
摘要： The present invention generally relates to a population of committed ventricular progenitor (CVP) cells and their use to generate a tissue engineered myocardium, in particular two dimensional tissue engineered myocardium which is comparable to functional ventricular heart muscle. One embodiment of present invention provides a composition and methods for the production of a tissue engineered myocardium which has functional properties of cardiac muscle, such as contractibility (e.g. contraction force) and numerous properties of mature fully functional ventricular heart muscle tissue. In particular, in one embodiment, a composition comprising the tissue engineered myocardium comprises committed ventricular progenitor (CVP) cells seeded on a free-standing biopolymer structure to form functional ventricular myocardium tissue.
摘要翻译：本发明一般涉及致心肌祖细胞（CVP）细胞群及其用于产生组织工程化心肌的用途，特别是与功能性心室肌肉相当的二维组织工程化心肌。本发明的一个实施方案提供了用于生产具有心肌功能特性的组织工程化心肌的组合物和方法，例如收缩性（例如收缩力）和成熟的完全功能性心室肌肉组织的许多性质。特别地，在一个实施方案中，包含组织改造心肌的组合物包括接种在独立的生物聚合物结构上以承载心室祖细胞（CVP）细胞以形成功能性心室心肌组织。

8. 发明申请

WO2010025364A2 A NOVEL LUCIFERASE REPORTER SYSTEM FOR NON-INVASIVE MONITORING OF NFkB ACTIVITY IN VITRO AND IN VIVO 审中-公开
标题翻译：一种用于血管内皮生长因子（NF）活性的非侵入性监测的新型LUCIFERASE报告系统
公开(公告)号：WO2010025364A2
公开(公告)日：2010-03-04
申请号：PCT/US2009/055361
申请日：2009-08-28
申请人： THE GENERAL HOSPITAL CORPORATION , TANNOUS, Bakhos A , BADR, Christian
发明人： TANNOUS, Bakhos A , BADR, Christian
IPC分类号： C12Q1/66 , G01N33/52
CPC分类号： G01N33/5023 , A01K2207/12 , A01K2267/0393 , C07K14/43509 , C12N15/86 , C12N2740/15043 , C12N2830/002 , C12N2830/40 , C12Q1/66 , C12Q1/6897
摘要： The present invention relates to assays, methods and cells to monitor the effect of agents on cell signalling pathways. In particular, the present invention relates to an assay for real-time, non-invasive monitoring of the effect of an agent which modulates (i.e. increases or decreases) a cell signalling pathway which is regulated by transcription factors which bind to transcription response elements (TREs) to regulate gene expression. In particular in some embodiments, the assay comprises a cell which comprises the nucleic acid encoding a secretable luciferase protein, such as Gaussia luciferase which is operatively linked to numerous tandem repeats of transcription response elements (TRE), and where the cell is contacted with an agent and an increase or decrease in the expression of the secretable luciferase identifies an agent which increase or decreases the cell signalling pathway respectively. In some embodiments, the assay is useful for identifying agents which increase or decrease the NF- B pathway. In some embodiments, the assay is useful to identify agents which increase or decrease the NF- B pathway in immune or inflammatory cells.
摘要翻译：本发明涉及用于监测试剂对细胞信号传导途径的影响的测定，方法和细胞。特别地，本发明涉及用于实时，非侵入性地监测调节（即增加或减少）由转录因子结合转录反应元件调节的细胞信号传导途径的作用的实验的测定法（ TREs）调节基因表达。具体地，在一些实施方案中，测定法包括细胞，其包含编码可分泌荧光素酶蛋白质的核酸，例如可操作地连接到转录应答元件（TRE）的多个串联重复序列的高斯荧光素酶，并且其中细胞与并且可分泌荧光素酶的表达的增加或减少分别鉴定增加或减少细胞信号传导途径的试剂。在一些实施方案中，该测定可用于鉴定增加或减少NF-B途径的试剂。在一些实施方案中，该测定可用于鉴定在免疫或炎症细胞中增加或减少NF-B途径的试剂。

9. 发明申请

WO2011038401A2 DRAWN SILK EGEL FIBERS AND METHODS OF MAKING SAME 审中-公开
标题翻译：绢丝织物及其制造方法
公开(公告)号：WO2011038401A2
公开(公告)日：2011-03-31
申请号：PCT/US2010/050565
申请日：2010-09-28
申请人： TRUSTEES OF TUFTS COLLEGE , LO, Tim Jia-Ching , LEISK, Gary G , KAPLAN, David L
发明人： LO, Tim Jia-Ching , LEISK, Gary G , KAPLAN, David L
IPC分类号： D01F4/02 , D01D5/00
CPC分类号： D01F4/02 , D01D1/02 , D01D5/00 , G02B6/02033
摘要： The present invention relates to compositions and method for drawing egel silk fibroin fibers. The resulting fibers can transmit light and hence can be used as optical fiber. Silk fibroin fiber is produced by a method comprising applying an electric field to a solubilized silk fibroin solution to create a silk fibroin gel; converting the silk fibroin gel to a viscous silk liquid; and drawing a silk fiber from the viscous silk liquid. The silk fiber of the invention can be used in materials such as textile, medical sutures, and tissue materials, as well as conferring optical properties into these materials.
摘要翻译：本发明涉及丝绒丝素纤维的制备方法。所得到的纤维可以透射光，因此可以用作光纤。丝素蛋白纤维通过包括向溶解的丝素蛋白溶液施加电场以产生丝素蛋白凝胶的方法产生; 将丝素蛋白凝胶转化成粘稠的丝液; 并从粘性丝液中抽出丝纤维。本发明的丝纤维可用于纺织品，医用缝合线和组织材料等材料，并可赋予这些材料光学性质。

10. 发明申请

WO2009134866A2 CELL MEMBRANE ENGINEERING 审中-公开
标题翻译：细胞膜工程
公开(公告)号：WO2009134866A2
公开(公告)日：2009-11-05
申请号：PCT/US2009/042087
申请日：2009-04-29
申请人： THE BRIGHAM AND WOMEN'S HOSPITAL, INC. , KARP, Jeffrey, M. , SARKAR, Debanjan , VEMULA, Praveen, Kumar
发明人： KARP, Jeffrey, M. , SARKAR, Debanjan , VEMULA, Praveen, Kumar
IPC分类号： C12N5/08 , C12N5/06 , A61K35/12
CPC分类号： A61K35/28 , A61K9/1647 , A61K39/00 , A61K47/549 , A61K47/6901 , C12N5/0006 , C12N5/0663
摘要： The present invention is directed to methods and compositions for engineering the surface of a cell, wherein a targeting moiety and/or a particle are attached to the cell membrane. The particle can further comprise a therapeutic agent for drug delivery. The compositions disclosed herein are useful in the treatment of diseased or damaged tissue by targeting cells for the purpose of tissue regeneration, drug delivery or a combination of both.
摘要翻译：本发明涉及用于工程化细胞表面的方法和组合物，其中靶向部分和/或颗粒附着于细胞膜。该颗粒可以进一步包含用于药物递送的治疗剂。本文公开的组合物可用于通过靶向细胞以治疗组织再生，药物递送或两者的组合来治疗患病或受损组织。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式